Media OutReach
New Report Calls for Collective Action to Combat Asia’s Growing Antimicrobial Resistance Threat
- The Centre for Impact Investing and Practices and the World Economic Forum’s GAEA (Giving to Amplify Earth Action) initiative, supported by the Philanthropy Asia Alliance, have released a study urging cross-sector investment to tackle antimicrobial resistance (AMR) in Asia.
- AMR could cost Asia up to US$700 billion by 2050 and surpass cancer as the world’s leading cause of death.
- Report outlines four high-impact intervention areas – from education and prevention to surveillance and treatment – to guide funders and partners.
SINGAPORE – Media OutReach Newswire – 5 May 2025 – The Centre for Impact Investing and Practices (CIIP) and the World Economic Forum’s GAEA (Giving to Amplify Earth Action) initiative, supported by the Philanthropy Asia Alliance (PAA), today launched the report — Targeted Action and Financing the Fight Against Antimicrobial Resistance in Asia.
The report underscores the urgent threat of antimicrobial resistance (AMR) in Asia and outlines four key areas where cross-sector funders can drive meaningful impact. It draws on insights from 15 case studies and examples of funding mechanisms, and contributions from 26 organisations, including international organisations, corporations, philanthropic funders, public institutions, and solution providers.
Often called the silent pandemic, AMR was linked to 4.7 million deaths annually in 2021.[1] It is estimated to become the leading cause of death by 2050, claiming more than 8 million lives[2] and surpassing cancer[3]. Beyond human health, AMR threatens global food systems by reducing global livestock production and polluting waterways. Tackling this growing crisis requires a unified, whole-of-ecosystem approach.
“Antimicrobial resistance is a mounting crisis that threatens to reverse decades of medical progress, with Asia at the epicenter of this challenge. We have identified clear needs, but no single organisation can tackle this alone and substantial philanthropic and catalytic funding is required. It demands all actors — across sectors and borders — to step up, pool resources, and collaborate. Together, we hope that through active partnerships, we can build a future where effective treatments remain within everyone’s reach,” said Ms. Dawn Chan, Chief Executive Officer, CIIP.
“The Davos Compact on Antimicrobial Resistance (AMR), launched earlier in January this year, seeks to mobilise public-private-philanthropic, cross sectoral collaboration to reduce the global and increasing threat of AMR. This report builds on the Davos Compact, highlighting practical, high impact interventions where catalytic investments can help safeguard health and well-being, reducing risks and deaths associated with AMR,” said Ms. Gim Huay Neo, Managing Director, Member of the Managing Board, World Economic Forum.
Asia: A Crucible for the Multifaceted AMR Challenge
Globally, nearly one in five AMR-related deaths occur in children under five[4], and two in three in adults over 65[5]. However, Asia bears the brunt of the disease incidence, accounting for more than half of the 4.71 million deaths worldwide associated with AMR in 2021[6]. Rising temperatures and extreme weather events are accelerating bacterial growth and disease transmission, while disrupting healthcare and immunisation services – particularly in regions with inadequate healthcare infrastructure and sanitation. These climate-related pressures are also driving the increased use of antimicrobials in livestock and crops, contaminating freshwater sources and fuelling drug resistance.
In Asia Pacific alone, AMR-related costs are projected to reach up to US$700 billion by 2050, accounting for up to 1% of the region’s GDP[7]. However, timely investment in AMR solutions could generate US$10–15 billion in annual healthcare savings, and cut annual socio-economic costs by up to US$40 billion for Asia Pacific within the next decade.[8] Tackling AMR is essential for health security, as well as ensuring long-term economic resilience and sustainable development.
A Unified Approach to Antimicrobial Development and Use
Despite research advancements, market and policy gaps make it challenging to bring new drugs to patients as the costs involved in development and regulatory approval tend to outweigh the immediate returns upon product launch. A One Health approach — one that recognises the interconnectedness and interdependence across humans, animals, plants, and the wider environment — is essential to tackle AMR sustainably.
While new therapeutics such as drugs and vaccines can take 10 to 15 years to develop and launch to market[9] (a marathon), immediate and practical interventions (sprints) are needed to curb resistance today and pave the way for long-term solutions.
The report thus proposes interventions in four areas:
- Sprint 1: Educate – Improving knowledge and behaviour by strengthening awareness of AMR among clinicians, patients, and farmers; emphasising the importance of avoiding the overuse or abuse of antimicrobials; as well as introducing strategies to prevent infections in the first place.
- Sprint 2: Prevent – Strengthening health systems and services by boosting preventive measures such as improving diagnostic capabilities and investing in better water, sanitation, and hygiene (WASH) measures.
- Sprint 3: Monitor – Enhancing regional surveillance, and data collection and sharing between actors, especially in lower-income countries.
- Marathon: Treat – Investing in research and development for new antimicrobials, and increasing access to novel and essential medicines.
Financing AMR Solutions At Every Stage
Private funders, impact investors, and philanthropists have a vital role to play in closing critical gaps – particularly in late-stage drug development, where funding is scarce. By pooling resources, funders can help bring life-saving treatments to market, strengthen the antibiotic pipeline, and build more sustainable and widespread access to essential medicines.
“This report is a catalyst for deeper involvement from all sectors — philanthropic, public, and private. It highlights the scale of the AMR threat and the opportunity for collective action. We are encouraged by the ongoing work of organisations – including PAA members like the Gates Foundation, Wellcome Trust, and Novo Nordisk Foundation – in driving AMR research and greater access to affordable solutions. Now is the time for more partners to come together, pool resources, and support high-impact solutions that safeguard health and resilience across Asia and beyond,” said Mr. Shaun Seow, Chief Executive Officer, PAA.
The AMR threat demands urgent, coordinated, and sustained action across healthcare, agriculture, and food systems to protect communities in Asia.
Read the full report here: https://ciip.com.sg/knowledge-hub/research-insights/Details/targeted-action-and-financing-the-fight-against-antimicrobial-resistance-in-asia
The issuer is solely responsible for the content of this announcement.
About the Centre for Impact Investing and Practices
The Centre for Impact Investing and Practices (CIIP) was established in 2022 as a non-profit entity by Temasek Trust to foster impact investing and practices in Asia and beyond by building and sharing knowledge, bringing together stakeholders in the community, and bringing about positive action that accelerates the adoption of impact investing principles and practices. CIIP is the anchor partner for the United Nation Development Programme’s Private Finance for the SDGs, providing Asia investors and businesses with clarity, insights and tools that support their contributions towards achieving the SDGs. Temasek and ABC Impact are CIIP’s strategic partners. For more information, please visit www.ciip.com.sg.
About GAEA (Giving to Amplify Earth Action)
To reach net zero, reverse nature loss and restore biodiversity by 2050, funding for equitable climate and nature transitions must be stepped up by more than $3 trillion annually. No actor can solve these issues alone; only together – through partnerships, elevated ambition and accelerated learning – can the most pressing problems facing the planet be solved. The World Economic Forum launched the GAEA (Giving to Amplify Earth Action) initiative to convene 4P – Public, Private and Philanthropic Partnerships – for climate and nature, activating systemic bold partnerships to improve the state of the world.
About Philanthropy Asia Alliance
Philanthropy Asia Alliance (PAA) is a Temasek Trust initiative dedicated to catalysing collaborative philanthropy in Asia through dynamic multi-sector partnerships. By harnessing collective strengths, PAA multiplies impact, accelerates positive change, and takes urgent action to address the pressing environmental and social challenges of our time. PAA’s flagship programme is the annual Philanthropy Asia Summit. For more information, visit http://philanthropyasiaalliance.org.
Media OutReach
St. George’s University Prepares Future South Korean Physicians for the Growing Global Cancer Care Challenge
Recognizing the importance of addressing workforce shortage in South Korea, St. George’s University (SGU) School of Medicine in Grenada, West Indies, highlights how its medical education approach supports the development of clinical competencies relevant to cancer care across healthcare settings.
These challenges reflect broader global trends, where cancer care increasingly depends on multidisciplinary teams rather than specialty expansion alone. SGU’s curriculum is designed to build a strong foundation in clinical diagnosis, patient communication and multidisciplinary care, which are essential skills for effective oncology and cancer-related care. Through anatomy labs, simulation-based learning, and integrated digital tools, students develop foundational clinical skills in structured, supervised environments designed to reflect real-world medical practice.
The curriculum also integrates traditional cadaveric dissection with modern 3D anatomical modeling. This blend helps students visualize the human body in a holistic way while reinforcing knowledge through their hands-on interaction. SGU’s simulation lab also enables medical students to have their first direct interaction with ill patients in a safe, simulated learning environment.
On top of core medical training, SGU offers early exposure to prevention, diagnosis and patient-centered care to prepare graduates to tackle complex health issues. SGU has developed long-standing relationships with more than 75 established hospitals and clinical centers in the US and UK. These clinical placements provide exposure to diverse patient populations and care environments, including settings where cancer diagnosis and management are part of routine clinical practice.
South Korean SGU alumni are contributing to healthcare systems through roles that intersect with cancer diagnosis, treatment coordination, and long-term patient care. For example, Dr. Julia Hweyryoung Cho, MD 2022 is practicing internal medicine, which plays a crucial role in cancer care. Internal medicine physicians are often involved in the initial diagnosis of cancer, managing complex medical conditions that may arise during treatment and providing long-term comprehensive care and survivorship planning for patients with a history of cancer.
In observance of World Cancer Day 2026, SGU encourages all medical professionals and organizations to collaboratively address global cancer care challenges. This includes recognizing and meeting the cancer healthcare needs of individuals and communities in South Korea.
For more information on the programs and tracks available through SGU School of Medicine, visit SGU’s website.Hashtag: #St.George’sUniversity
The issuer is solely responsible for the content of this announcement.
Media OutReach
Finalists and Semifinalists for $1 Million Seeding The Future Global Food System Challenge Announced
Created and funded by Seeding The Future Foundation and, for the first time, hosted by Welthungerhilfe (WHH), the Challenge attracted a record 1,600+ applications from innovator teams in 112 countries, underscoring growing global momentum for food systems transformation.
Following a multi-stage, rigorous international review process, 36 teams have advanced across three award levels. These include 16 Seed Grant Finalists (competing for 8 awards of USD 25,000), 12 Growth Grant Semifinalists (competing for 3 awards of USD 100,000), and 8 Seeding The Future Grand Prize Semifinalists (competing for 2 awards of USD 250,000).
“Hosting the GFSC reflects Welthungerhilfe’s commitment to accelerating bold, scalable innovations where they are needed most. This year’s diversity of solutions underscores the complexity of food system challenges and the creativity of innovators worldwide.” said Jan Kever, Head of Innovation at Welthungerhilfe
The submitted innovations span diverse themes and approaches, including climate-smart production, nutrient-dense foods, food loss reduction, and inclusive market models, reflecting the complexity and interconnected nature of today’s food systems challenges.
“The Seeding The Future Global Food System Challenge exists to catalyze impactful, bold, and scalable innovations that advance food systems transformation. We are excited to work alongside Welthungerhilfe as a trusted partner and host of the Challenge and are encouraged by the quality and diversity of innovations emerging from this first year of collaboration.” said Bernhard van Lengerich, Founder and CEO of Seeding The Future Foundation
While the number of awards is limited, all semifinalists and finalist applicants plus all applicants with any prior recognition of other innovation competitions can join the STF Global Food System Innovation Database and Network—currently in beta testing with the Food and Agriculture Organization of the United Nations—vastly expanding their visibility and reach across a global audience.
List of 2025 GFSC Seed Grant Finalists, Growth Grant and Seeding The Future Grand Prize Semifinalists
Find details here: welthungerhilfe.org/gfsc-finalists
Seeding The Future Grand Prize Semi-Finalists
- CNF Global, Kenya
- ZTN Technology PLC, Ethiopia
- One Acre Fund, Rwanda
- Sanku, Tanzania
- Nabahya Food Institute (NFI), Democratic Republic of the Congo
- ABALOBI, South Africa
- metaBIX Biotech, Uruguay
- Nurture Posterity International, Uganda
Growth Grant Semi-Finalists
- Baobaby, Togo
- Safi International Technologies Inc., Canada
- Centro Internacional de Mejoramiento de Maíz y Trigo (CIMMYT), Mexico
- Farmlab Yeranda Agrisolution Producer Company Limited, India
- Banco de Alimentos Santa Fe (BASFE), Argentina
- Chartered Consilorum (Pty) Ltd, South Africa
- American University of Beirut, Environment and Sustainable Development Unit (ESDU at AUB), Lebanon
- The Source Plus, Kenya
- Iviani Farm Limited, Kenya
- Rwandese Endogenous Development Association, Rwanda
- NatureLEAD, Madagascar
- Ndaloh Heritage Organisation, Kenya
Seed Grant Finalists
- Inua Damsite CBO, Kenya
- World Neighbors, United States
- Keloks Technologies Ltd, Nigeria
- REBUS Albania, Albania
- Tanzania Conservation and Community Empowerment Initiative (TACCEI), Tanzania
- Intrasect, Switzerland
- VKS AGRITECH, India
- Murmushi People’s Development Foundation, Nigeria
- Levo International, Inc., United States
- Effective Altruism Research Services Ltd, Uganda
- Taita Taveta University, Kenya
- CultivaHub, Democratic Republic of the Congo
- Resource Hub for Development (RHD), Kenya
- FUTURALGA S.COOP.AND, Spain
- West Africa Centre for Crop Improvement, University of Ghana, Ghana
- Sustainable Solutions Kenya, Kenya
Hashtag: #TheFutureGlobalFoodSystemChallenge
The issuer is solely responsible for the content of this announcement.
About Seeding The Future Foundation
STF is a private nonprofit dedicated to ensuring equitable access to safe, nutritious, affordable, and trusted food. It supports innovations that transform food systems and benefit both people and planet. More at Seeding the future.
About Welthungerhilfe
WHH is one of Germany’s largest private aid organizations, striving for a world without hunger since 1962. More at: Welthungerhilfe (WHH)
Media OutReach
PolyU develops novel antibody targeting fat cell protein, offering new approach to treating metabolism-related liver cancer
Metabolic dysfunction-associated steatotic liver disease (MASLD), commonly known as fatty liver disease, currently affects around a quarter of the global population and is an important risk factor for liver cancer. In affected individuals, fat cells induce insulin resistance and chronic inflammation, leading to excessive fat accumulation in the liver. This ultimately impairs liver function and may progress to liver cancer. Treatment options for MASLD-induced liver cancer remain limited and the effectiveness of current immunotherapies is suboptimal.
A breakthrough study led by Prof. Terence LEE, Associate Head and Professor of the PolyU Department of Applied Biology and Chemical Technology, and his research team has revealed that an adipocyte-derived protein, known as fatty acid-binding protein 4 (FABP4) is a key driver that accelerates tumour growth. Through mass spectrometry, the team confirmed that patients with MASLD-induced liver cancer had markedly elevated FABP4 levels in their serum. Further investigations showed that FABP4 activates a series of pro-proliferative signalling pathways within cells, causing cancer cells to multiply and grow more rapidly.
Prof. Lee’s team has successfully developed a monoclonal antibody that neutralises FABP4. This antibody not only inhibits the growth and proliferation of FABP4-driven cancer stem cells, but also enhances the ability of immune cells to combat cancer.
Prof. Lee said, “This neutralising antibody against FABP4 demonstrates significant potential in inhibiting tumour growth and activating immune cells, providing a complementary approach to current immunotherapy strategies. Our findings highlight that targeting adipocyte-derived FABP4 holds promise for treating MASLD-induced liver cancer.”
Prof. Lee added that gaining deeper insights into how adipocyte-derived FABP4 affects liver cancer cells helps to explicate the disease mechanisms of liver cancer, particularly in obese individuals. Intervening in the relevant signalling pathways could provide effective methods to combat this aggressive malignancy.
Prof. Lee believes that, as this adipocyte-targeted immunotherapy continues to mature, it will bring more treatment options to MASLD patients. He remarked, “If its efficacy can be proven in clinical trials, it could offer new hope to many affected individuals.”
The research is supported by the Innovation and Technology Fund of the Innovation and Technology Commission of the Government of the Hong Kong Special Administrative Region of the People’s Republic of China. PolyU has filed a non-provisional patent for the developed antibody and is continuing to optimise its binding affinity to facilitate future clinical applications.
Hashtag: #PolyU #FattyLiver #Cancer #LiverCancer #理大 #香港理工大学 #肝癌 #癌症 #脂肪肝
The issuer is solely responsible for the content of this announcement.
-
Feature/OPED6 years agoDavos was Different this year
-
Travel/Tourism9 years ago
Lagos Seals Western Lodge Hotel In Ikorodu
-
Showbiz3 years agoEstranged Lover Releases Videos of Empress Njamah Bathing
-
Banking8 years agoSort Codes of GTBank Branches in Nigeria
-
Economy3 years agoSubsidy Removal: CNG at N130 Per Litre Cheaper Than Petrol—IPMAN
-
Banking3 years agoSort Codes of UBA Branches in Nigeria
-
Banking3 years agoFirst Bank Announces Planned Downtime
-
Sports3 years agoHighest Paid Nigerian Footballer – How Much Do Nigerian Footballers Earn